Current strategies for salvage treatment for relapsed classical Hodgkin lymphoma
Open Access
- 29 August 2017
- journal article
- review article
- Published by SAGE Publications in Therapeutic Advances in Hematology
- Vol. 8 (10), 293-302
- https://doi.org/10.1177/2040620717728000
Abstract
Hodgkin lymphoma (HL) is curable in 70–80% of patients with first-line therapy. However, relapses occur in a minority of patients with favorable early stage disease and are more frequent in patients with advanced HL. Salvage chemotherapy followed by high-dose chemotherapy and autologous stem cell transplant (ASCT) for patients with chemotherapy-sensitive disease is a standard treatment sequence for relapsed or refractory (rel/ref) HL. Patients who achieve complete response prior to ASCT have better survival outcomes. The choice of salvage chemotherapy therapy is becoming increasingly difficult in the era of novel agents, as there are no randomized studies to guide the choice of a second-line regimen. In this article, we will review current salvage therapy options, including combination chemotherapy and novel-agent-based salvage regimens for rel/ref HL.Keywords
This publication has 65 references indexed in Scilit:
- Pegylated liposomal doxorubicin: an efficient treatment in patients with Hodgkin lymphoma relapsing after high dose therapy and stem cell transplationBritish Journal of Haematology, 2013
- Phase II Study of Bendamustine in Relapsed and Refractory Hodgkin LymphomaJournal of Clinical Oncology, 2013
- Results of a Pivotal Phase II Study of Brentuximab Vedotin for Patients With Relapsed or Refractory Hodgkin's LymphomaJournal of Clinical Oncology, 2012
- Positron emission tomography response at the time of autologous stem cell transplantation predicts outcome of patients with relapsed and/or refractory Hodgkin's lymphoma responding to prior salvage therapyHaematologica, 2012
- A phase 2 multicenter study of lenalidomide in relapsed or refractory classical Hodgkin lymphomaBlood, 2011
- Brentuximab Vedotin (SGN-35) for Relapsed CD30-Positive LymphomasThe New England Journal of Medicine, 2010
- Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphomaBlood, 2010
- Long-term outcome of autologous stem-cell transplantation in relapsed or refractory Hodgkin's lymphomaAnnals of Oncology, 2008
- Nonmyeloablative Stem Cell Transplantation Is an Effective Therapy for Refractory or Relapsed Hodgkin Lymphoma: Results of a Spanish Prospective Cooperative ProtocolTransplantation and Cellular Therapy, 2006
- Salvage Radiotherapy in Patients With Relapsed and Refractory Hodgkin’s Lymphoma: A Retrospective Analysis From the German Hodgkin Lymphoma Study GroupJournal of Clinical Oncology, 2005